Loading people...
Dov Goldstein is a Managing Partner at Aisling Capital, a prominent private equity firm focused on the life sciences industry. He is a seasoned investor with extensive experience in pharmaceuticals, biotechnology, and medical devices.
Dov Goldstein primarily invests in the life sciences sector, including pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services, and digital health solutions. He targets innovative companies with high growth potential.
Dov Goldstein works as a Managing Partner at Aisling Capital, a leading private equity firm specializing in healthcare investments.
Dov Goldstein stands as a distinguished figure in the life sciences investment landscape, currently serving as a Managing Partner at Aisling Capital. Aisling Capital is a leading private equity firm renowned for its strategic investments in companies poised to revolutionize healthcare through groundbreaking advancements. Goldstein's leadership is instrumental in guiding the firm's investment strategy, particularly within the dynamic and critical sectors of pharmaceuticals, biotechnology, and medical devices. His expertise extends to diagnostics, healthcare services, and emerging digital health solutions, reflecting a comprehensive understanding of the evolving healthcare ecosystem.
At Aisling Capital, Dov Goldstein plays a pivotal role in identifying promising early to late-stage private companies, as well as select public entities, that possess the potential for significant impact and growth. He is deeply involved in all aspects of the investment process, from initial due diligence and deal structuring to providing strategic oversight and mentorship to portfolio companies. His approach is characterized by a keen analytical mind combined with a deep industry network, enabling him to spot opportunities that others might overlook and to foster the development of innovative therapies and technologies.
Goldstein's impressive career trajectory before joining Aisling Capital provided him with a robust foundation in healthcare finance. Prior to his current role, he held a significant position as a Managing Director in the healthcare group at Credit Suisse First Boston. In this capacity, he advised numerous pharmaceutical, biotechnology, and medical device companies on complex financial transactions, including mergers and acquisitions, corporate finance, and capital raising initiatives. His earlier experience as a healthcare investment banker at Salomon Smith Barney further honed his skills in strategic financial advisory within the life sciences sector.
Academically, Dov Goldstein is well-credentialed, holding an MBA from Columbia Business School, a testament to his strong business acumen. He also earned a Bachelor of Arts degree from the University of Pennsylvania, providing him with a broad intellectual foundation. This blend of rigorous academic training and extensive practical experience in high-stakes financial environments has equipped him with a unique perspective on value creation in healthcare.
Throughout his career, Goldstein has been a champion of innovation, often serving on the boards of directors for numerous innovative healthcare companies within Aisling Capital's portfolio. While specific investments are proprietary, his influence is evident in the strategic direction and growth of many companies that have gone on to achieve significant milestones in drug development, medical technology, and patient care. His commitment to advancing healthcare through strategic capital deployment underscores his reputation as a thoughtful and impactful investor in the global life sciences industry.
Dov Goldstein is a Managing Partner at Aisling Capital based in New York, where he oversees strategic life sciences investments and portfolio company development. He previously served as Chief Financial Officer of Loxo Oncology prior to its $8 billion acquisition by Eli Lilly, and helped lead Vicuron Pharmaceuticals before its $1.9 billion sale to Pfizer. His extensive executive background also includes impactful tenures as Chief Executive Officer at RIGImmune, Chief Financial Officer at both Schrödinger and BioAge Labs, and Chief Business Officer at Indapta Therapeutics. He earned an MD from the Yale School of Medicine, an MBA from Columbia Business School, and a BS from Stanford University. Today, Goldstein leverages his unique medical background to guide clinical-stage biopharmaceutical companies, maintaining active board positions at prominent biotechnology firms including Gain Therapeutics and ADMA Biologics.
